 FOSTER CITY, Calif.--BUSINESS WIRE--Geron Corporation Nasdaq: GERN, a late-stage clinical biopharmaceutical company, today announced achievement of fifty percent enrollment in the IMerge Phase 3 clinical trial of imetelstat in lower risk myelodysplastic syndromes MDS. Data from the IMerge Phase 2 were recently presented at the American Society of Hematology Annual Meeting and support the ongoing Phase 3. Reaching fifty percent enrollment is a key milestone towards the completion of this 